Our study demonstrated that among ER + HER2- breast cancer patients treated with NAC, those with tumors exhibiting high sTIL levels achieved higher pCR rates, an effect that appeared more pronounced in HG III tumor. The gene discussed is ERBB2; the disease is breast carcinoma.